Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Eukaryotic Gene Expression
Factor de Impacto: 1.841 Factor de Impacto de 5 años: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v6.i2-3.50
pages 189-214

Utilization of Nuclear Matrix Proteins for Cancer Diagnosis

Susan K. Keesee
Matritech, Inc., 330 Nevada St., Newton, MA 02160
Joseph V. Briggman
Matritech, Inc., 330 Nevada St., Newton, MA 02160
Gregory Thill
Matritech, Inc., 330 Nevada St., Newton, MA 02160
Ying-Jye Wu
Matritech, Inc., 330 Nevada St., Newton, MA 02160


Circulating tumor markers have been used increasingly in recent years as clinical tools for cancer diagnosis and management. This review presents a brief discussion of currently available tumor-associated antigens. Included is an overview of different functional classes of circulating markers and their clinical applications. The limitations of some traditional tumor markers presently in widespread use are discussed in the context of the properties exhibited by an ideal tumor marker. The nuclear matrix provides structural support for the nucleus and plays a dynamic role in the spatial organization of the genome and in the control of DNA replication and transcription. The recovery of increased amounts of specific nuclear matrix proteins in several different cancers has led to the further study of some of these proteins as a new class of tumor markers. Progress on the use of a nuclear matrix protein known as NuMA as a marker for bladder cancer is presented, including results of a recently completed multisite clinical trial. Additional studies on the potential utility of nuclear matrix proteins as markers for prostate cancer are also presented. Nuclear matrix proteins could provide for the development of assays with increased efficacy for the diagnosis and treatment of cancer.

Articles with similar content:

Oncogenic Potential of Yin Yang 1 Mediated Through Control of Imprinted Genes
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Michelle M. Thiaville , Joomyeong Kim
Interfering with Nuclear Transport as a Means of Interrupting Transcription Factor Activity in Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 5
Pauline J. van der Watt, Aderonke F. Ajayi-Smith, Virna D. Leaner
Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies
Critical Reviews™ in Oncogenesis, Vol.11, 2000, issue 1
Waldemar Debinski, Akiva Mintz
Stem Cell Marker OCT3/4 in Tumor Biology and Germ Cell Tumor Diagnostics: History and Future
Critical Reviews™ in Oncogenesis, Vol.12, 2006, issue 3-4
Jeroen de Jong, Leendert H. J. Looijenga
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida